Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2004

01-09-2004 | Author’s Reply

MHC class II expression by beta cells in Type 1 diabetes: promoting or inhibiting the autoimmune process? A reply to D. W. R. Gray

Authors: U. Walter, W. A. Scherbaum, J. Buer

Published in: Diabetologia | Issue 9/2004

Login to get access

Excerpt

To the Editor: The role of MHC class II expression by pancreatic beta cells in Type 1 diabetes is of central interest to our understanding of the autoimmune process and is a highly controversially issue, which has been discussed for the past two decades. In a recent publication, we showed that beta cells from non-obese diabetic (NOD) mice express MHC class II protein and that the frequency of beta cells positive for I-Ag7 mRNA strongly increases during progression to overt hyperglycaemia. We proposed that this MHC class II expression by beta cells may make them a direct target of autoreactive CD4+ T cells and that this may be a critical disease-promoting event [1]. …
Literature
1.
Walter U, Toepfer T, Dittmar KE et al. (2003) Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia 46:1106–1114CrossRefPubMed
2.
Gray DWR (1999) Type 1 diabetes: the facts fit a deficient inhibitory signal given by MHC Class II. Diabet Metab Res Rev 5:29–34
3.
Gray DWR (2004) To: Walter U, Toepfer T, Dittmar KE et al. (2003) Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes, Diabetologia 46:1106–1114. Diabetologia 47:143CrossRefPubMed
Metadata
Title
MHC class II expression by beta cells in Type 1 diabetes: promoting or inhibiting the autoimmune process? A reply to D. W. R. Gray
Authors
U. Walter
W. A. Scherbaum
J. Buer
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1476-6

Other articles of this Issue 9/2004

Diabetologia 9/2004 Go to the issue

Book reviews

R. Hanas (2002) Type 1 Diabetes in children, adolescents and young adults. How to become an expert on your own diabetes. Second edition. Class Publishing, London, UK. (ISBN 1 85959 078 0)

Article

Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients

Article

Conformation-dependent GAD65 autoantibodies in diabetes

EASD

EASD News Section September 2004

Authors’ Reply

Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31–39

Article

Maternal dietary vitamin restriction increases body fat content but not insulin resistance in WNIN rat offspring up to 6 months of age
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits